Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ: ANIP) will be reporting earnings this Friday before the bell. Here’s what to look for.
ANI Pharmaceuticals beat analysts’ revenue expectations by 9.8% last quarter, reporting revenues of $197.1 million, up 43.4% year on year. It was a very strong quarter for the company, with a solid beat of analysts’ EPS estimates and full-year revenue guidance slightly topping analysts’ expectations.
Is ANI Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting ANI Pharmaceuticals’s revenue to grow 38.7% year on year to $191.5 million, improving from the 18.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.42 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. ANI Pharmaceuticals has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 6.9% on average.
Looking at ANI Pharmaceuticals’s peers in the pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Amneal delivered year-on-year revenue growth of 3.2%, missing analysts’ expectations by 2.5%, and Bristol-Myers Squibb reported flat revenue, topping estimates by 7.8%. Amneal’s stock price was unchanged after the resultswhile Bristol-Myers Squibb was down 3.9%.
Read our full analysis of Amneal’s results here and Bristol-Myers Squibb’s results here.
The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the pharmaceuticals stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 5.7% on average over the last month. ANI Pharmaceuticals is up 6.2% during the same time and is heading into earnings with an average analyst price target of $81.38 (compared to the current share price of $69.09).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
